Mentioned Users

Humira (Adalimumab) is a biologic drug approved by the U.S. Food and Drug Administration (FDA) to treat moderate to severe hidradenitis suppurativa (HS) in people 12 and older. Here are some key points about Humira:

- Mechanism: Humira is a genetically engineered antibody that neutralizes tumor necrosis factor alpha Show Full Answer

Humira (Adalimumab) is a biologic drug approved by the U.S. Food and Drug Administration (FDA) to treat moderate to severe hidradenitis suppurativa (HS) in people 12 and older. Here are some key points about Humira:

- Mechanism: Humira is a genetically engineered antibody that neutralizes tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.
- Administration: After an initial loading dose, Humira is administered every week or every other week by subcutaneous injection. It is available as a single-dose prefilled pen or syringe.
- Side Effects: Common side effects include respiratory infections, headache, redness or irritation at injection sites, and rash. Rare but serious side effects include severe allergic reactions, potentially fatal infections, new or worsening heart failure, lupus-like syndrome, demyelinating disease (such as multiple sclerosis), and an increased risk of certain types of cancer such as lymphoma.

For more details, you can visit the [Humira page on myHSteam](https://www.myHSteam.com/treatments/humira).

 This AI-generated response comes from myHSteam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Humira (Adalimumab) for Hidradenitis suppurativa | myHSteam

Is HS an Autoimmune Condition? | myHSteam